Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NRAS G12X |
| Therapy | Daraxonrasib |
| Indication/Tumor Type | pancreatic ductal adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS G12X | pancreatic ductal adenocarcinoma | sensitive | Daraxonrasib | Phase III | Actionable | In a Phase III trial (RASolute 302), treatment with Daraxonrasib (RMB-6236) in patients with metastatic pancreatic ductal adenocarcinoma significantly improved median overall survival (mOS, 13.2 vs 6.6 mo, HR=0.40, p<0.001) and median progression-free survival (mPFS, 7.3 vs 3.5 mo, HR=0.45, p<0.001) compared to chemotherapy in patients harboring a RAS G12 mutation, and mOS (13.2 vs 6.7 mo, HR=0.40, p<0.001) and mPFS (7.2 vs 3.6 mo, HR=0.49, p<0.001) in the overall cohort (PMID: 42223072; NCT06625320). | 42223072 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42223072) | Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. | Full reference... |